This study is being conducted to confirm the performance of the Archimedes System in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung cancer or metastatic disease.
|Current Primary Outcome Measures||Proportion of biopsies yielding tissue sufficient for diagnosis
The number of nodules with at least one biopsy sufficient for a definitive tissue diagnosis divided by the number of nodules sampled by the Archimedes System.
|Current Secondary Outcome Measures||• Procedure planning time
The time from selecting the patient CT until the tunnel path has been selected, reviewed and exported
• Nodule access time
The time from the start of navigation until the sheath has been placed at the first biopsy target.
• Fluoroscopy time
The total fluoroscopy time from the start of fused-fluoroscopic navigational guidance to the time the devices are removed from the point of entry.
• Patient registration time
The total time it takes to correlate the patient’s position via fluoroscopy with the navigational guidance system.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT02867371
|United States, Oklahoma|
|Cancer Treatment Centers of America at Southwestern Regional Medical Center
Tulsa, Oklahoma, United States, 74133
Contact: Daniel Nader, D.O. 918-286-5000
Contact: Faye Biggs (918) 286-5000
Principal Investigator: Daniel Nader, D.O.
|United States, Pennsylvania|
|Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
Contact: Gerard J. Criner, MD 215-717-2000
Contact: JiJi Thomas (215) 717-2000
Principal Investigator: Gerard J. Criner, MD
|The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact: Shiyue Li, M.D.
Principal Investigator: Shiyue Li, M.D.
|Shanghai General Hospital
Shanghai, Shanghai, China
Contact: Jiayuan Sun, M.D.
Principal Investigator: Jiayuan Sun, M.D.
Contact: Felix Herth, M.D.
Principal Investigator: Felix Herth, M.D.